News Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-13 pm EDT			5-day change	1st Jan Change
85.49 ^USD	+1.75%		-6.26%	-16.30%

Mar. 11	Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM
Mar. 11	Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year	RE

All News

Mar. 13	New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare	BU
Mar. 11	Guardant Health, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:00 PM
Mar. 11	Braidwell, Karnal and Kreiter's AI healthcare fund, surged 28% last year	RE
Mar. 10	Guardant Health Inc Announces Shield Blood-Based Screening Test for Colorectal Cancer Is Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	CI
Mar. 10	Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics	BU
Mar. 05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
Mar. 04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
Mar. 04	Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America	BU
Mar. 03	Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened	BU
Feb. 27	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
Feb. 19	Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026
Feb. 19	Guardant Health: Q4 Earnings Snapshot	AQ
Feb. 19	Guardant Health : Q4 and Full Year 2025 Earnings Call	PU
Feb. 19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
Feb. 19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT
Feb. 19	Earnings Flash (GH) Guardant Health, Inc. Reports Q4 Revenue $281.3M, vs. FactSet Est of $272.4M	MT
Feb. 19	Earnings Flash (GH) Guardant Health, Inc. Posts Q4 Adjusted Loss $0.50 per Share, vs. FactSet Est of $-0.77	MT
Feb. 19	Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook	BU
Feb. 19	Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 19	Guardant Health, Inc. Provides Revenue Guidance for the Fiscal Year 2026	CI
Feb. 18	Guardant Health, Inc. (NasdaqGS:GH) acquired Metasight Diagnostics for approximately $150 million.	CI
Feb. 17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
Feb. 12	Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open	PR
Feb. 12	Single‑Reference Disclosures And The Motivation‑To‑Combine Requirement	AQ
Feb. 03	Guardant Health to Participate in Upcoming Investor Conferences	BU